Risky Business: Addressing Misconceptions About 2025 Drug and Device Inspections

May 1, 2025 | 2:00PM–3:30PM ET | Live Webinar

Overview

Risky Business: Addressing 2025 Drug and Device Inspections
May 1, 2025 | 2:00PM – 3:30PM ET | Live Webinar
 
This webinar prepares stakeholders for a transformative new phase in FDA’s inspection and enforcement practices. Shifts in these practices demand strategic foresight from leaders across drugs and device industries and preparedness to handle all types of inspection tools. This panel addresses the current state of FDA inspections and shifts in budgetary priorities and personnel count that will affect their approach and timing. Attendees from domestic and global manufacturers will learn what to realistically expect from FDA as the agency implements these changes, where to expect risk, and the importance of internal improvements to be successful in any environment.

Register

$149

Members

$249

Non-Members

$29

Student

Speakers

Donald Ashley
Read Bio
Principal, Regulatory Compliance, ELIQUENT Life Sciences

Ricki A. Chase
Read Bio
President, RChase Consulting LLC

Benjamin K. Wolf
Read Bio
Partner, Alston & Bird LLP

Moderated by Elizabeth Mulkey
Read Bio
Partner, Goodwin Procter LLP